Get the Stockscreener App
10.28
0.10%
0.010
Eikon Therapeutics Inc stock is traded at $10.28, with a volume of 148.52K.
It is up +0.10% in the last 24 hours and up +3.84% over the past month.
Eikon Therapeutics Inc is a late-stage clinical biopharmaceutical company dedicated to building a world-wide , fully-integrated organization developing important, medicines to address serious unmet medical needs. It operates in a single operating segment, which is in the business of drug discovery leveraging its proprietary technology and clinical development of its product candidates. Its product candidates include: EIK1001, EIK1003, EIK1004, EIK1005, and EIK1006.
See More
Previous Close:
$10.27
Open:
$10.28
24h Volume:
148.52K
Relative Volume:
0.47
Market Cap:
$556.54M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+20.09%
1M Performance:
+3.84%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.05
$10.66
1-Week Range:
$8.3301
$10.66
52-Week Range:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Name
Eikon Therapeutics Inc
Sector
Industry
Phone
341-777-0566
Address
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
10.28 | 556.54M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-26 | Initiated | BofA Securities | Buy |
| Mar-02-26 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-02-26 | Initiated | JP Morgan | Overweight |
| Mar-02-26 | Initiated | Mizuho | Outperform |
| Mar-02-26 | Initiated | Morgan Stanley | Overweight |
| Feb-26-26 | Initiated | Wedbush | Underperform |
View All
Eikon Therapeutics Inc Stock (EIKN) Latest News
EIKN SEC FilingsEikon Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
[SCHEDULE 13G] Eikon Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Domino's Posts Downbeat Q1 Results, Joins Real Brokerage And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Merck reportedly eyeing $30M stake in Eikon Therapeutics’ IPO - MSN
Merck veteran-led Eikon seeks $908M valuation in US IPO - MSN
Should I be cautious with Eikon Therapeutics (EIKN) stock today (Market Focus) 2026-04-20Most Discussed Stocks - Xã Châu Thành
IPO Tracker 2026: Seaport, Hemab set sail for Nasdaq - BioSpace
ETFs Investing in Eikon Therapeutics, Inc. Stocks - TradingView
EIKN: Eikon Therapeutics, Inc.Comparison to Industry - Zacks Investment Research
EIKN : Eikon Therapeutics, Inc. Key Company Metrics & Non-finance Metrics - Zacks Investment Research
Eikon Therapeutics, Inc. News — NASDAQ:EIKN - TradingView
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Diluted shares outstanding of Eikon Therapeutics, Inc. – BX:EIKN - TradingView — Track All Markets
Number of employees of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Statistics – BX:EIKN - TradingView — Track All Markets
EIKN Price Today: Eikon Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC
IPO market strengthens in Q1 2026 as biopharma financings reach $22.82B - BioWorld News
Should I buy Eikon Therapeutics, Inc. (EIKN) - Zacks Investment Research
EIKN Analyst Rating Reiterated at Underperform by Wedbush | EIKN Stock News - GuruFocus
Eikon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update By Investing.com - Investing.com Canada
Mizuho reiterates Eikon Therapeutics stock rating on pipeline update - Investing.com
IPO Tracker 2026: Biotech Mega-Rounder Kailera Seeks IPO - BioSpace
Eikon Therapeutics Reports 2025 Financial Results, Upsized IPO, and Key Clinical Pipeline Progress - Minichart
Eikon Therapeutics Reports Q4 and Full Year 2025 Results, Provides Clinical Updates - National Today
Eikon Gains on Results - Baystreet.ca
Eikon Therapeutics Announces Fourth Quarter And Full Year 2025 Financial Results And Provides Clinical And Corporate Updates - TradingView
Eikon Therapeutics: Advancing Biopharmaceutical Innovation with Proprietary Technology Platform and Clinical-Stage Oncology Pipeline - minichart.com.sg
Eikon Therapeutics Announces Fourth Quarter and Full Year - GlobeNewswire
After a $381M IPO, Eikon fully enrolls a stage 4 lung cancer study - Stock Titan
Form 10-K Eikon Therapeutics, Inc. For: Dec 31 - StreetInsider
Eikon Therapeutics (NASDAQ: EIKN) posts 2025 loss but extends cash runway - Stock Titan
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P TMI Index - MarketScreener
Eikon Therapeutics (EIKN) Stock Analysis Report | Financials & Insights - Benzinga Japan
Eikon Therapeutics (EIKN) grants 25,873-share stock option award to director - Stock Titan
Eikon Therapeutics (EIKN) grants director Kenneth Frazier 25,873 options - Stock Titan
Large stock option grant to Eikon Therapeutics (EIKN) director and officer - Stock Titan
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage By Investing.com - Investing.com Canada
Eikon Therapeutics Shares Jump 6% as Brokerages Initiate Coverage - Investing.com UK
BofA initiates Eikon Therapeutics stock with buy rating on platform potential - Investing.com Australia
BofA Securities Initiates Eikon Therapeutics at Buy With $34 Price Target - marketscreener.com
Cantor Fitzgerald Initiates Eikon Therapeutics at Overweight - marketscreener.com
This NextTrip Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Mizuho Initiates Eikon Therapeutics at Outperform With $26 Price Target - marketscreener.com
BofA initiates Eikon Therapeutics stock with buy rating on platform potential By Investing.com - Investing.com South Africa
Morgan Stanley Initiates Eikon Therapeutics at Overweight With $32 Price Target - marketscreener.com
Mizuho initiates Eikon Therapeutics stock coverage with outperform - Investing.com Nigeria
JPMorgan initiates Eikon Therapeutics stock at Overweight By Investing.com - Investing.com Nigeria
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight By Investing.com - Investing.com South Africa
Morgan Stanley initiates Eikon Therapeutics stock coverage at overweight - Investing.com India
Eikon Therapeutics Inc Stock (EIKN) Financials Data
There is no financial data for Eikon Therapeutics Inc (EIKN). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):